Last reviewed · How we verify
Blood sample at D1, D3 and D7
At a glance
| Generic name | Blood sample at D1, D3 and D7 |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Role of Fibrinolytic Activity in Neoplastic Pathologies Complicated by Coagulopathy
- E-assisted Follow up Diagnosis of Post Operative Digestive Complications (NA)
- Prognostic Impact of Neopterin on Resumption of Walking After a Fracture of the Upper Neck of the Femur in the Elderly (NA)
- AB122 Platform Study (PHASE1)
- Optimizing Long-term Survival in Organ Transplantation: From Physiopathology to Optimized Patient Management (NA)
- Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML (PHASE1, PHASE2)
- LIPId Profile Changes in Inflammatory Conditions Induced by SARS-CORoronavirus-2
- Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Blood sample at D1, D3 and D7 CI brief — competitive landscape report
- Blood sample at D1, D3 and D7 updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI